To the Editor:Despite optimal secondary prevention treatments,a large proportion of patients with coronary artery disease(CAD)after percutaneous coronary intervention(PCI)are still at a high risk of recurrent cardiova...To the Editor:Despite optimal secondary prevention treatments,a large proportion of patients with coronary artery disease(CAD)after percutaneous coronary intervention(PCI)are still at a high risk of recurrent cardiovascular events.Inflammation is a well-known component of residual cardiovascular risk and contributes to progression of atherosclerosis,leading to destabilization and rupture of atheroma plaques.^([1])As a downstream protein in the activated inflammatory pathway that mediates the progression of atherosclerosis,high-sensitivity C-reactive protein(hsCRP)is widely used as a biomarker of inflammatory status and predictor of adverse outcomes in the settings of primary and secondary prevention of cardiovascular disease.展开更多
基金supported by grants from the National Clinical Research Center for Cardiovascular Diseases,Fuwai Hospital,Chinese Academy of Medical Sciences(No.NCRC2020013)CAMS Innovation Fund for Medical Sciences(No.2020-12M-C&T-B-049).
文摘To the Editor:Despite optimal secondary prevention treatments,a large proportion of patients with coronary artery disease(CAD)after percutaneous coronary intervention(PCI)are still at a high risk of recurrent cardiovascular events.Inflammation is a well-known component of residual cardiovascular risk and contributes to progression of atherosclerosis,leading to destabilization and rupture of atheroma plaques.^([1])As a downstream protein in the activated inflammatory pathway that mediates the progression of atherosclerosis,high-sensitivity C-reactive protein(hsCRP)is widely used as a biomarker of inflammatory status and predictor of adverse outcomes in the settings of primary and secondary prevention of cardiovascular disease.
